Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?

被引：1

作者：

Ouissam, Al Jarroudi ^{[1
,2
]}

Hind, Chibani ^{[1
,2
]}

Aziz, Brahmi Sami ^{[1
,2
]}

Said, Afqir ^{[1
,2
]}

机构：

[1] Mohammed VI Univ Hosp, Dept Med Oncol, Oujda, Morocco

[2] Mohammed Ist Univ, Fac Med & Pharm, Oujda, Morocco

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2024年 / 16卷

关键词：

clinical trials; genetic alterations; pancreatic ductal adenocarcinoma; PI3K/AKT/mTOR pathway; targeted therapy; GROWTH-FACTOR RECEPTOR; 1ST-IN-HUMAN PHASE-I; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; PI3K INHIBITOR; PHOSPHOINOSITIDE; 3-KINASE; PI3K/MTOR INHIBITOR; ANTITUMOR-ACTIVITY; BUPARLISIB BKM120;

D O I：

10.1177/17588359241284911

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer (PC) is an aggressive disease that is challenging to treat and is associated with a high mortality rate. The most common type of PC is pancreatic ductal adenocarcinoma (PDAC), and the existing treatment options are insufficient for PDAC patients. Due to the complexity and heterogeneity of PDAC, personalized medicine is necessary for effectively treating this illness. To achieve this, it is essential to understand the mechanism of PDAC carcinogenesis. Targeted therapies are a promising strategy to improve patient outcomes. Aberrant activation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway plays a crucial role in PC pathogenesis, from initiation to progression. This review provides a comprehensive overview of the current state of knowledge regarding the PI3K pathway in PDAC, summarizes clinical data on PI3K pathway inhibition in PDAC, and explores potential effective combinations that are a promising direction requiring further investigation in PDAC.

引用

页数：21

共 50 条

[31] Quantification of PI3K/AKT/mTOR pathway inhibition is predictive of biological response
Van Brussel, A.
Wesseling-Rozendaal, Y.
Den Biezen, E.
Neerken, S.
van de Wiel, P.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S81 - S81
[32] RAS Signaling in the PI3K/AKT/MTOR Pathway
Nussinov, Ruth
Zhang, Mingzhen
Jang, Hyunbum
BIOPHYSICAL JOURNAL, 2020, 118 (03) : 51A - 51A
[33] THE PI3K/AKT MTOR PATHWAY IN OLIGODENDROCYTE DIFFERENTIATION
Wood, T.
Tyler, W.
Gangoli, N.
Gokina, P.
Kim, H.
Covey, M.
Levison, S.
GLIA, 2009, 57 (13) : S20 - S20
[34] Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects
Stanciu, Silviu
Ionita-Radu, Florentina
Stefani, Constantin
Miricescu, Daniela
Stanescu-Spinu, Iulia-Ioana
Greabu, Maria
Totan, Alexandra Ripszky
Jinga, Mariana
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
[35] PI3K/AKT/mTOR
Umemura, Shigeki
Goto, Koichi
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S116 - S117
[36] Frequent Aberrant Activation of the PI3K/Akt/mTOR Pathway in Pancreatic Endocrine Tumors
Zhou, X. P.
Frankel, W. L.
Bloomston, M.
Iwenofu, O. H.
Bellizzi, A. M.
LABORATORY INVESTIGATION, 2009, 89 : 327A - 327A
[37] PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy
Liu, Hua
Zhang, Liqin
Zhang, Xuyan
Cui, Zhumei
ONCOTARGETS AND THERAPY, 2017, 10 : 2865 - 2871
[38] Frequent Aberrant Activation of the PI3K/Akt/mTOR Pathway in Pancreatic Endocrine Tumors
Zhou, X. P.
Frankel, W. L.
Bloomston, M.
Iwenofu, O. H.
Bellizzi, A. M.
MODERN PATHOLOGY, 2009, 22 : 327A - 327A
[39] The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Paplomata, Elisavet
O'Regan, Ruth
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (04) : 154 - 166
[40] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
Li, HaiXia
Zeng, JianFang
Shen, Keng
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2014, 290 (06) : 1067 - 1078

← 1 2 3 4 5 →